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Background: Several epidemiological studies showed a close association between metabolic control and
microvascular complications in type 1 Diabetes Mellitus (T1DM). The aim of our longitudinal observational
study was to evaluate the predictive role of the main clinical and biochemical parameters in determining
microvascular complications.
Methods: 376 T1DM patients, hospitalized in our division from 1991 to 2005 (mean follow-up=10.93±
4.26 years) were studied. Stepwise Cox regression analysis was used to identify the influence of residual ß-cell
function, ß-cell autoimmunity, HbA1c levels and other clinical and laboratory parameters in the development of
microalbuminuria and retinopathy.
Results: The probability of developing microalbuminuria was higher in males than in females (HR 1.82; 95%
CI 1.01–3.28; p=0.044), in patients with higher mean HbA1c values (HR 2.80; 95% CI 1.63–4.83; pb0.001),
longer duration of disease (HR 1.98; 95% CI 1.10–3.57; p=0.022) and younger age of diabetes onset (HR 0.53;
95% CI 0.03–0.92; p=0.026). An increased probability of developing retinopathy was found in patients with
higher mean HbA1c levels during follow-up (HR 2.35; 95% CI 1.34–4.12, p=0.003), as well as at onset (HR 1.85;
95% CI 1.06–3.24; p=0.030).
Conclusions: Our study suggests that among the clinical, metabolic, immunological and biochemical factors
evaluated at onset, only HbA1c is predictive for the microangiopathy development in T1DM.
© 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Several epidemiological studies have shown a close association
between metabolic control and microvascular complications in type 1
Diabetes Mellitus (T1DM) [1–4]. In particular, the Diabetes Control and
Complications Trial (DCCT) has emphasized that optimization of blood
glucose levels with intensive insulin treatment reduces the develop-
ment and progression of microvascular complications [5,6]. Concerning
micro- and macroalbuminuria, the cumulative prevalence in T1DM
patients is 34%after about18 years of diabetes, regardless of age at onset
[7], while cumulative prevalence of microalbuminuria in patients with
childhood onset is 12–25% after 5–10 years of disease [8–12]. As regards
retinopathy, the 2000 ADA recommendations suggest that vision-
threatening retinopathy does not occur during the first 3–5 years,
although it is developed by almost all T1DM patients about 20 yearsy (Dipartimento di Oncologia
sità di Palermo, Piazza delle
; fax: +39 0916552123.
ration of Internal Medicine. Publishafter onset. By contrast, the WESDR study (conducted on 137 patients)
reported 49% positive findings for retinopathy when diabetes duration
is ≤4 years [13]. These results were further confirmed by DCCT (1613
patients) which showed a percentage of retinopathy of at least 67.1%
with diabetes duration b5 years [5]. Concerning residualβ-cell function,
the Diabetes Prevention Trial-1 (DPT-1) indicated that a decrease in
insulin secretion occurs from pre-diabetes to clinical onset [14,15].
Fasting C-peptide is usuallymaintained at diagnosis [16,17]. In addition,
DCCT reported that a stimulated C-peptide level of ≥0.2 pmol/ml was
correlated with improved metabolic control and a decreased rate of
complications when compared to patients with C-peptide levels below
this threshold [18]. Stimulated C-peptide levels N0.2 pmol/ml were
found in 33% of subjects b18 years of age and in 48% of subjects
N18 years of agewith a disease duration of b5 years. As regards autoim-
munity, several cross-sectional studies indicated absence of correlation
between diabetes-associated autoantibodies and long-term develop-
ment of microvascular complications [19,20]. The aim of this longitu-
dinal observational study was to evaluate in newly-diagnosed T1DM
patients, admitted to our Division of Endocrinology and Metabolic
Diseases, the predictive role of residual β-cell function, β-cell specific
autoantibodies, HbA1c levels and other clinical parameters regarding
the development of microvascular complications.ed by Elsevier B.V. All rights reserved.
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Among the 1118 Sicilian patients consecutively hospitalized in our
Division from 1991 to 2005 for T1DM, we selected only those with
diabetes at onset who were treatment-naïve (376 patients), with
specific beta-cell autoimmunity (with or without ketosis or ketoaci-
dosis at onset) or with ketosis or ketoacidosis at onset in the absence
of autoimmunity, with weight loss N10% (from at least 6 months)
and/or polyuria for more than 6 months before diagnosis. The selected
patients [224 males (59.6%) and 152 females (40.4%); aged 20.23±
8.47 years (range 2–46)] were longitudinally studied from diagnosis,
with amean follow-up of 10.93±4.26 (range 4–18) years. All patients
included had been subsequently treated with conventional basal-
bolus insulin therapy. During follow-up, patients underwent at least
twomedical examinations per year and clinical reports were recorded
in our case files. Specifically, we extrapolated the following data:
gender, age at onset, duration of disease, use of tobacco (current or
former smoker/never smoker), body mass index (BMI) at onset and
after 1 year, mean systolic and diastolic blood pressures, fundus oculi
and intraocular pressure (tonometry), microalbuminuria, Glucagon
Stimulated C-peptide (GSC-pep) test at onset and at year 1, insulin
requirement (unit/kg body weight) at onset and at year 1, HbA1c (%)Table 1
Characteristics of T1DM patients grouped on the basis of age at onset tertiles.
b15
No
Age at onset (yrs)⁎ 11.2




BMI at onset (kg/m2)⁎ 19.9
BMI at 1 year (kg/m2)⁎ 20.3




Positive autoantibodies 1 at 1 year
GADAc 64
IA-2Ad 50














AUCGSC-pep 15 min at onset 5.48
AUCGSC-pep 15 min at 1 year 8.21
Insulin requirement at onset (U/kg)⁎ 0.60
Insulin requirement at 1 year (U/kg)⁎ 0.51
HbA1c (%) at onset 9.36
HbA1c (%) at 1 year⁎ 7.70
Mean HbA1c (%) before the onset of complications or of the entire disease 8.14
Presence of diabetic retinopathy 17
Presence of microalbuminuria 18
Diabetic retinopathy onset⁎ (semester from diagnosis)e 22.7
Microalbuminuria onset⁎ (semester from diagnosis)e 22.1
Data are presented as mean±SD for quantitative variables and No (%) for categorical varia
⁎ Significant differences among the 3 groups (Univariate ANOVA; pb0.001).
a Percentages differ significantly (χ2 test, p=0.021).
b Percentages differ significantly (χ2 test, p=0.015).
c Percentages differ significantly (χ2 test, p=0.032).
d Percentages differ significantly (χ2 test, p=0.019).
e Six-month period.at onset and at year 1, mean HbA1c, pancreatic autoimmunity [GAD
antibodies (GADA), IA-2 antibodies (IA-2A) and insulin autoantibo-
dies (IAA)]. IAA were determined at onset, while GADA and IA-2A
at onset and after 1 year. Mean values of HbA1c, and systolic and
diastolic blood pressures were calculated during the entire follow-up
period (for patients without complications up to 2009) or until the
onset of microalbuminuria and/or diabetic retinopathy (for patients
with complications). The Institutional Review Board of the University
of Palermo approved the study and patients gave informed consent
for recording and scientific use of their data.
2.1. Laboratory analysis
Routine chemistry/hematology blood analyses were performed on
patients in external laboratories. HbA1c, C-peptide, pancreatic
autoantibodies and microalbuminuria were assessed in our central-
ized laboratory. HbA1c was determined by means of High Pressure
Liquid Chromatography (HPLC) with ion-exchange resin (HA8121,
Hi-AutoA1c, Menarini, Italy). Serum C-peptide was measured by
ELISA (DRG C-peptide ELISA, Germany). The conversion factor for the
International System (ng/dl versus nmol/L) was 0.33. All subjects
were evaluated for pancreatic autoimmunity at onset and at monthyears 15–23 years N23 years Total
125 No 126 No 125 No 376
4±3.42 19.13±2.09 30.32±5.46 20.23±8.47
2±4.25 10.88±4.22 9.90±4.08 10.93±4.26
(64.8) 67 (53.2) 76 (60.8) 224 (59.6)
(35.2) 59 (46.8) 49 (39.2) 152 (40.4)
3±2.87 21.60±2.50 23.04±2.52 21.52±2.92
0±2.59 21.98±2.17 23.16±2.83 21.81±2.79
(60.8) 92 (73) 85 (68) 253 (67.3)
(41.6) 62 (49.2) 40 (32) 154 (40.9)
115 (32.2) 26/102 (25.5) 14/94 (14.9) 77/311 (24.8)
(51.2) 85 (67.5) 74 (59.2) 223 (59.3)
(40) 59 (46.9) 37 (29.6) 146 (38.8)
±0.19 0.28±0.24 0.24±0.23 0.25±0.22
±0.27 0.45±0.40 0.41±0.49 0.41±0.40
±0.28 0.47±0.40 0.45±0.53 0.43±0.42
±0.33 0.50±0.49 0.42±0.42 0.44±0.42
±0.29 0.38±0.27 0.44±0.59 0.39±0.41
±0.26 0.48±0.51 0.42±0.46 0.42±0.43
±0.14 0.25±0.16 0.23±0.15 0.25±0.15
±0.23 0.46±0.33 0.43±0.31 0.44±0.29
±0.25 0.46±0.23 0.47±0.28 0.47±0.25
±0.40 0.56±0.40 0.59±0.48 0.58±0.43
±0.44 0.55±0.37 0.56±0.38 0.57±0.40
±0.25 0.58±0.47 0.52±0.27 0.55±0.34
±4.00 6.70±5.28 6.44±6.87 6.21±5.52
±4.51 7.93±4.98 7.92±4.98 8.02±4.82
±0.28 0.47±0.21 0.34±0.18 0.47±0.25
±0.25 0.44±0.25 0.32±0.18 0.42±0.24
±2.10 9.48±2.26 9.27±2.29 9.37±2.21
±1.68 7.40±1.55 6.82±1.58 7.31±1.64
±1.31 7.69±1.25 7.62±1.17 7.82±1.27
(13.6) 19 (15.1) 14 (11.2) 50 (13.3)
(14.4) 16 (12.7) 22 (17.6) 56 (14.9)
4±8.25 20.44±7.96 18.67±7.56 20.61±8.08
3±8.84 20.41±8.52 17.91±7.91 20.15±8.58
bles.
Fig. 1. Beta cell function assessed through GSC-pep test showing significantly higher
values at 1 year in comparison to diabetes onset. A. Error bars represent standard
deviation (SD) of the means. B. Error bars represent standard error (SE) of the means.
Significant differences (paired t-test).
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immunologic test (RIA) (Adaltis Kit). Values were considered positive
for GADA N4.39 relative units (RU) and for IA-2A N0.81 RU. For IAA
measurement we used a custom-made RIA test. Cut-off values were
based on the 99th percentile of more than 40 Sicilian normal subjects,
aged 12–30 years. Measurements were validated by our participation
in the Diabetes Autoantibody Standardization Program (DASP), which
showed sensitivity of 87% and specificity of 96% for GADA assay,
sensitivity of 83% and specificity of 100% for IA-2A assay and
sensitivity of 79% and specificity of 100% for IAA.
Microalbuminuria was assessed by immunoturbidimetric assay
(ArrayProtein System360, Beckman,USA)on a24-hoururine collection.
2.2. GSC-pep test
Pancreatic β-cell function was assessed in all patients by GSC-pep
test at diagnosis (after correction of ketosis or ketoacidosis and
stabilization of blood glucose levels) and at year 1. Basal and
stimulated C-peptide were performed in the morning after an
overnight fasting period of 8–10 h. Patients took no short-acting
insulin for at least 6 h and bedtime long-acting insulin at least 12 h
before the test. The testwas performedonly if fasting glucosewas 72 to
200 mg/dl (4 to 11.1 mmol/L). 1 mg of glucagon (0.03 mg/kg of weight
in children, maximum 1 mg) was intravenously injected within 10 s
[21]. Samples were drawn at 1, 3, 6, 10 and 15 min after the end of
glucagon administration.
2.3. Assessment of microalbuminuria
Microalbuminuria was defined for albumin levels of 30–300 mg in a
24-h urine collection [22]. Assessment was performed routinely every
6–12 months, along with a microbiological urinalysis to exclude
infections. The onset was established as the semester in whichmicroal-
buminuria was first found positive in two out of three consecutive tests.
2.4. Assessment of diabetic retinopathy
Diabetic retinopathy was classified according to the Diabetic
Retinopathy Working Party screening recommendations [23]. The
onset was established as the semester in which at least one single red
lesion (dot or larger) or bright lesion (hard exudate, cottonwool spot)
was observed in at least one eye. Screeningwas performed once a year
and standard retinal photographs were taken.
2.5. Statistical analysis
All data were analyzed using statistical software SPSS Version 17
for Windows. Baseline characteristics were calculated as mean±
standard deviation (SD) for continuous variables and as rates and
proportions for categorical data. The C-peptide area under the curve
(AUC) during GSC-pep (AUCGSC-pep 15 min) was computed from all
timed collections (including the basal one) using the trapezoidal
method. Normality of distribution for quantitative data was assessed
by the Kolmogorov–Smirnov test. The one-way ANOVA was used for
differences in means within more than two groups and by χ2-test and
Fisher's exact test (when appropriate) for categorical variables. The
ANOVA trend analysis and χ2-test for trend were used to assess
means and proportions of the population characteristics across
grouped type 1 diabetic patients on the basis of β-cell function. The
Kaplan–Meier survival analysis was used to estimate the probability
of developingmicroalbuminuria and diabetic retinopathy and the log-
rank test was performed to compare survival curves. Two forward
stepwise Cox proportional-hazard regression models, with p values
for entry of covariates into the regression set at 0.10 were generated
to investigate the contribution of each covariate in the development of
complications (microalbuminuria, and diabetic retinopathy). MeanHbA1c, systolic and diastolic blood pressures were defined as the
mean values calculated from the onset of diabetes to the onset of
complications (in patients with complications) or mean values of the
entire disease (in patients without complications). Variables were
removed from the models for p valueN0.10. In the models, the
variable for time was the duration of diabetes expressed in semesters
and the variables for status were onset of microalbuminuria and
diabetic retinopathy, treated as dichotomous categorical values. A
p value of b0.05 was considered statistically significant.
3. Results
3.1. Clinical characteristics
Fifty-six subjects (14.9%) out of the total cohort of 376 patients
developed microalbuminuria and fifty patients (13.3%) developed
diabetic retinopathy. After subdividing the total population into three
groups according to disease duration, we found the following
prevalence distribution: group 4–8 years [microalbuminuria 11.8%
(16/136), retinopathy 3.7% (5/136)]; group 9–13 years [microalbu-
minuria 5% (6/121), retinopathy 3.6% (8/121)]; group 14–18 years
[microalbuminuria 28.6% (34/119), retinopathy 31.1% (37/119)]. Mean
age at onset of diabetes was 20.23±8.47 years (range 2–46) and
showedGaussiandistribution.Whendividingpatients into threegroups
in relation to tertiles of age at diagnosis (b15 years, 15–23 years and
N23 years) we did not find any significant difference between BMI at
onset and 1 year later, though a trend of progressive increase was seen
269C. Giordano et al. / European Journal of Internal Medicine 22 (2011) 266–274as the tertile increased (Table 1). With regard to GADA, no difference
was found at onset between the three groups, while after 1 year the
group 15–23 years showed a higher prevalence of positivity (67.5%).
The higher prevalence of IA-2A was found in the 15–23 year group,
both at onset and after 1 year. IAA at onset were higher in the first
tertile. The percentage of negative patients for all the antibodies both
at onset and after 1 year was 19.68% (74/376). No difference was found
between the three groups concerning C-peptide secretion (GSC-pep,
AUCGSC-pep 15 min both at onset and 1 year later). Based on age at
diagnosis, the first tertile (younger patients) showed significantly
higher levels of insulin requirement and HbA1c both at onset and after
1 year. With regard to microalbuminuria and retinopathy prevalence
we found no differences between the three groups (Table 1).3.2. β-cell function during the first year of disease
A difference in AUCGSC-pep 15 min was found in all 376 patients,
with significantly higher values at 1 year in comparison to onset
(8.02±4.82 versus 6.21±5.52; pb0.001): this difference was not
related to GSC-pep values at 0′, 1′ and 3′, but to those at 6′, 10′ and
15′ (Fig. 1). In addition, patients were subdivided on the basis of
insulin secretion changes 1 year after diabetes onset calculated as the
ratio between AUCGSC-pep 15 min (after 1 year) and AUCGSC-pep 15 min (at
onset) (AUCGSC-pep ratio). To identify those subjects who showed
deteriorated, unchanged or improved pancreatic β-cell function 1 year
after diagnosis, we divided all patients into two groups (those with
AUCGSC-pep ratio ≤ or N1). The patients with AUCGSC-pep ratio between
0.81 (equivalent to the 75th percentile of the first group) and 1.32
(equivalent to the 25th percentile of the second group) were defined asTable 2
Characteristics of T1DM patients grouped on the basis of β-cell function.
Dβ
No




BMI at onset (kg/m2) 21.
Delta BMI (kg/m2) 0.3
AUCGSC-pep 15 min at onset⁎ 13.
AUCGSC-pep 15 min at 1 year⁎ 5.5
Positivity of IAA at onset 17/
Evolution of GAD autoimmunity (1 year)
GADA−onset/GADA−1 year⁎ 5 (
GADA+onset/GADA+1 year⁎ 45
GADA−onset/GADA+1 year 4 (
GADA+onset/GADA−1 year 7 (
Evolution of IA2 autoimmunity (1 year)
IA2−onset/IA2−1 year 29
IA2+onset/IA2+1 year 24
IA2−onset/IA2+1 year 1 (
IA2+onset/IA2−1 year 7 (
Number of antibodies (first year of disease)
No antibodies⁎ 2 (
Only GADA 27
Only IA2 3 (
GADA+IA2⁎ 29
IR at onset (U/kg) 0.4
Delta IR (U/kg) −0
HbA1c at onset 9.4
Delta HbA1c (%) −2
Mean HbA1c (%) before the onset of complications or of the entire disease 7.9
DβCF: Deteriorated β-Cell Function after 1 year; UβCF: Unchanged β-Cell Function after 1 y
Data are presented as mean±SD for quantitative variables and No (%) for categorical varia
a ANOVA trend analysis.
b Chi-squared test for trend.
⁎ Significant values when pb0.05.having an unchanged function. We therefore identified three groups
(Table 2):
- patients with AUCGSC-pep ratio≤0.81 [Deteriorated β-Cell Function
after 1 year (DβCF)];
- patients with AUCGSC-pep ratioN0.81 and ≤1.32 [Unchanged β-Cell
Function after 1 year (UβCF)];
- patients with AUCGSC-pep ratio N1.32 [Improved β-Cell Function
after 1 year (IβCF)].
The IβCF group showed no differences in the mean HbA1c levels in
comparison to DβCF and UβCF. A significant increasing trend of
prevalence of GADA negative patients (DβCF=8.2%; UβCF=28.6%;
IβCF=34.8%; pb0.001) and absence of both antibodies (DβCF=3.3%;
UβCF=17.6%; IβCF=25%; pb0.001) from onset to a one-year cut-off
point was observed among the three groups, while GADA positivity
had an inverse trend (DβCF=73.8%; UβCF=57.1%; IβCF=50%;
p=0.001). No significant difference was found for IA-2A positivity,
BMI and insulin requirement (Table 2).
3.3. Contribution of different clinical and laboratory parameters to the
development of microalbuminuria and diabetic retinopathy in
multivariate analysis
The variables that showed a p valueb0.10 at log-rank test (Fig. 2)
were included in the multivariate analysis. For the development of
microalbuminuria the variables not included were GAD and IA2 at
1 year, AUCGSC-pep 15 min at 1 year, C-peptide trend (AUCGSC-pep ratio)
during the first year, HbA1c at onset and use of tobacco (current or
former smoker). In the final model, the probability of developingCF patients UβCF patients IβCF patients p value for
trend
61 No 91 No 224
75±8.08 19.71±8.74 20.03±8.91 0.281a
0.279b
(57.4) 49 (53.8) 140 (62.5)
(42.6) 42 (46.2) 84 (37.5)
84±3.28 21.19±2.54 21.57±2.96 0.829a
1±1.24 0.45±1.10 0.21±1.58 0.372a
55±9.13 7.05±2.83 3.87±2.24 b0.001a
7±3.95 7.64±2.61 8.84±5.45 b0.001a
61 (27.8) 20/91 (21.9) 40/224 (17.8) 0.078b
8.2) 26 (28.6) 78 (34.8) b0.001b
(73.8) 52 (57.1) 112 (50) 0.001b
6.6) 3 (3.3) 7 (3.1) 0.268b
11.5) 10 (11) 27 (12.1) 0.844b
(47.5) 48 (52.7) 124 (55.4) 0.281b
(39.3) 30 (33) 71 (31.7) 0.297b
1.6) 10 (11) 10 (4.5) 0.975b
11.5) 3 (3.3) 19 (8.5) 0.883b
3.3) 16 (17.6) 56 (25) b0.001b
(44.3) 32 (35.2) 68 (30.4) 0.042b
4.9) 10 (11) 22 (9.8) 0.368b
(47.5) 33 (36.3) 78 (34.8) 0.098b
8±0.23 0.44±0.23 0.47±0.27 0.803a
.03±0.23 −0.06±0.24 −0.02±0.23 0.525a
5±2.44 9.63±2.24 9.24±2.14 0.311a
.10±2.93 −2.39±2.80 −1.91±2.45 0.350a
2±1.25 7.78±1.38 7.80±1.23 0.633a
ear; IβCF: Improved β-Cell Function after 1 year.
bles.
Fig. 2. Univariate analysis of cumulative risk for the development of microvascular complications (Kaplan–Meier survival curves). The variables that showed a p valueb0.10 at log-
rank test were included in themultivariate analysis. The variables included for the development ofmicroalbuminuria (A) were diastolic blood pressure (DBP), systolic blood pressure
(SBP), mean HbA1c, BMI at onset, duration of disease, male gender, and age at onset. The variables included for the development of diabetic retinopathy (B) were mean HbA1c,
HbA1c at onset, BMI at onset, IA2 positivity, and duration of disease. * Dichotomous variables (0 = I and II tertiles; 1 = III tertile).
270 C. Giordano et al. / European Journal of Internal Medicine 22 (2011) 266–274microalbuminuria was higher inmales compared to females (HR 1.82;
95% CI 1.01–3.28; p=0.044), in patients with higher mean HbA1c
values (HR 2.80; 95% CI 1.63–4.83; pb0.001), longer duration of
disease (HR 1.98; 95% CI 1.10–3.57; p=0.022), younger age of
diabetes onset (HR 0.53; 95% CI 0.03–0.92; p=0.026) and lower
diastolic blood pressure levels (HR 0.48; 95% CI 0.25–0.89; p=0.021)
(Table 3).
With regard to the development of diabetic retinopathy, the
variables not included in the multivariate analysis were age at onset,
male gender, GAD at 1 year, AUCGSC-pep 15 min at 1 year, C-peptide
trend (AUCGSC-pep ratio) during the first year, mean systolic and
diastolic blood pressures and use of tobacco (current or former
smoker). The final stepwise proportional hazard model showed an
increased probability of developing retinopathy in patients with
higher mean (HR 2.35; 95% CI 1.34–4.12; p=0.003) and at onset
(HR 1.85; 95% CI 1.06–3.24; p=0.030) HbA1c levels (Table 3; Fig. 3).
4. Discussion
Our study investigated the occurrence of early microvascular
complications in a group of 376 patients with type 1 diabetes. We
found that 14.9% of patients developed microalbuminuria and 13.3%
developed diabetic retinopathy during a mean follow-up period of11 years (range 4–18 years). These results are in accordance with
DCCT, which reported 10% for retinopathy and 15% for nephropathy
over a 10-year period [5], and with previous studies [11,24–28]. With
regard to the evaluation of pancreatic reserve, DCCT individuated the
cut-off level of 0.2 mmol/L after a mixed meal tolerance test (MMTT)
to identify patients with residual β-cell function. In our study we used
GSC-peptide as our cohort is based on outpatients' clinical records
tracing back to 1991. Since the GSC-pep test does not have any
definite cut-off reference point, we evaluated residual β-cell function
during the first year as the ratio between AUCGSC-pep at 1 year and at
onset, thus arbitrarily identifying DβCF, UβCF and IβCF patients. We
observed significant improvement in the pancreatic β-cell function at
1 year in terms of AUCGSC-pep in the entire cohort. It is to be noted that
this improvement was mainly due to increased C-peptide values only
in the late phases of the test (6′, 10′ and 15′). This suggests that
probably there is no real recovery of β-cell mass, but a phenomenon of
regranulation of β-cells which were temporarily “exhausted” at the
time of diagnosis of diabetes [29]. In addition, we cannot rule out the
possibility of a non-physiological effect of glucagon on the residual
β-cell mass, perhaps not occurring with the more physiological
MMTT [30]. This hypothesis is further supported by the observation
that the 227 IβCF patients (60.37% of the whole group) did not show
any difference with respect to DβCF and UβCF regarding insulin
Table 3
Association of different variables with development of microalbuminuria and diabetic retinopathy using a forward stepwise Cox proportional hazards regression model.
Variables included in the equation p value Hazard ratio 95% CI for hazard ratio
Development of microalbuminuria
STEP 1
III tertile of mean HbA1c b0.001 2.78 1.64 4.72
STEP 2
DBPb80 mm Hg 0.007 0.42 0.22 0.79
III tertile of mean HbA1c 0.001 2.52 1.47 4.32
STEP 3
III tertile of disease duration 0.038 1.84 1.03 3.29
DBPb80 mm Hg 0.006 0.42 0.22 0.78
III tertile of mean HbA1c 0.001 2.52 1.47 4.32
STEP 4
III tertile of age at onset 0.041 0.56 0.32 0.97
III tertile of disease duration 0.026 1.93 1.08 3.47
III tertile of mean HbA1c b0.001 2.67 1.55 4.58
DBPb80 mm Hg 0.011 0.49 0.24 0.83
STEP 5
Male gender 0.044 1.82 1.01 3.28
III tertile of age at onset 0.026 0.53 0.03 0.92
III tertile of disease duration 0.022 1.98 1.10 3.57
III tertile of mean HbA1c b0.001 2.80 1.63 4.83
DBPb80 mm Hg 0.021 0.48 0.25 0.89
Variables not included in themodel: GAD and IA2 autoimmunity at 1 year, AUCGSC-pep 15 min at 1 year, C-peptide trend during the first year, HbA1c at onset and use of tobacco
(current or former smoker) (each pN0.10).
Development of diabetic retinopathy
STEP 1
III tertile of mean HbA1c 0.001 2.49 1.42 4.35
STEP 2
III tertile of HbA1c at onset 0.030 1.85 1.06 3.24
III tertile of mean HbA1c 0.003 2.35 1.34 4.12
Variables not included in the model: age at onset, gender (males), GAD at 1 year, AUCGSC-pep 15 min 1 year later, C-peptide trend during the first year, mean systolic and
diastolic blood pressures and use of tobacco (current or former smoker) (each pN0.10).
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reasonably be expected if real β-cell recovery occurred. Certainly, it
could be argued that the AUCGSC-pep ratio does not provide absolute
quantitative measurement of the residual β-cell function, but is a
mere qualitative evaluation regarding the possible improvement or
deterioration trend of the β-cell mass during the whole of the first
year. Nevertheless, it is quite intriguing that DβCF patients (18.61% of
the whole group) show the lowest rate (2.9%) of antibody negativity
and the highest rate of double autoimmunity (GAD+IA-2) (51.4%),
This observation confirms that the positivity for multiple diabetes-
associated autoantibodies, rather than for the individual antibody,
reflects a more severe disease process [31,32].
Concerning the evaluation of determinant factors for the devel-
opment of microvascular complications, our results confirmed that
themean value of HbA1c from the diagnosis of diabetes to the onset of
complication is predictive of both microalbuminuria and diabetic
retinopathy. It is noteworthy that higher HbA1c at diagnosis only
predicts retinopathy. As regards gender, the probability of developing
microalbuminuria was higher in males compared to females (espe-
cially in patients with a higher onset age), while no correlations were
found with retinopathy. This is in accordance with previous studies
which showed higher prevalence of microalbuminuria in men
compared with women [33], in particular in subjects with poor
control [34]. Whether this is caused by a direct effect of sex hormones
on the kidney or on body fat distribution leading to differences in
albumin excretion rate remains to be determined [35]. BMI,
pancreatic β-cell autoimmunity, basal and GSC-pep did not correlate
with microvascular complications, while the duration of diabetes
seemed to influence microalbuminuria. Lower diastolic blood pres-
sure levels were associated with microalbuminuria without a cause–
effect relationship; this apparently surprising datum can be explained
by the confounding statistical effect due to the antihypertensive
therapy administered to patients with microalbuminuria as soon as
the latter was evidenced, as suggested by the ADA guidelines [22].With regard to the influence of HbA1c levels, it is well known that the
risk of developing microvascular complications is significantly
reduced in the intensive versus the conventionally treated group
during the first 4 years, despite the similar HbA1c levels over this
period (so-called “metabolic memory”) [36]. This long-term influence
of early metabolic control on clinical outcomes is supported by ample
experimental evidence [37–40]. Surprisingly, our study revealed that
the value of HbA1c at diagnosis only affects diabetic retinopathy and
not microalbuminuria. This suggests that only retinal endothelium,
and not glomerular endothelium, records the “first” glycotoxic insult.
Hence, the reported abnormality in the eNOS/NO system of diabetic
angiopathy could be an expression of the different behavior in
different endothelial districts [41]. The primary role played by HbA1c
at the onset of diabetes has recently been corroborated by an
International Expert Committee, which suggested that standardized
HbA1c values are useful for the diagnosis of diabetes [42]. Similarly, a
recent study proposed a 6.6 to 7.0% HbA1c cut-off point for the diag-
nosis of diabetes, confirming it as the best value for the identification
of individuals with mild and moderate retinopathy [43]. In our study,
the onset of microvascular complications, both retinal and renal, did
not seem to be affected by the pancreatic β-cell reserve expressed by
AUCGSC-pep after 1 year. This observation apparently disagrees with
several studies reporting that the preservation of β-cell function results
in easier and better glycemic control and fewer end-organ complica-
tions, especially retinopathy [44–47]. In particular, the DCCT experience
widely demonstrated the clinical benefits of preservation of β-cell
function. DCCT described the relative risk of development and
progression of retinopathy and nephropathy by comparing baseline
responders (mixed-meal-stimulated C-peptide N0.2 mmol/L) versus
non-responders (mixed-meal-stimulated C-peptide b0.2 mmol/L) sep-
arately within the intensive and conventional treatment groups [48].
However, the beneficial effect of β-cell preservation was only observed
in the intensive therapy group, as conventionally treated responders
had similar risks for the progression of retinopathy and for the
Fig. 3. Cumulative risk (Kaplan–Meier survival curves) for the development of microvascular complications (microalbuminuria, and diabetic retinopathy) for gender (A), for HbA1c
at onset (based in tertiles of HbA1c) (B), for mean HbA1c before the onset of complications or of the entire disease (based in tertiles of HbA1c) (C).
272 C. Giordano et al. / European Journal of Internal Medicine 22 (2011) 266–274development of microalbuminuria. This is therefore in accordance with
our results, as our cohort of patients had higher mean HbA1c (7.82%) in
comparison to the DCTT patients in the intensive therapy group, and
similar mean HbA1c to the conventionally treated group. Furthermore,
the multivariate models used in many analyses of the DCCT data used a
correction for a lower number of covariates in comparison to our study.
This might explain the lack of an independent influence of residual
β-cell function on the development of complications found in our
study. In our opinion, the independent protective effect of residual
β-cell function on the development of microvascular complications
in type 1 diabetes still requires confirmation in larger clinical studies.
Other additional factors could influence the risk to develop micro-
vascular complications, such as familial insulin resistance (Type 2
diabetes in relatives of Type 1 diabetic patients) and shared geneticbasis for complications, perhaps independent of T1DM susceptibility,
as previously suggested [49–51].
In conclusion, our study not only confirms what was already
known about the role of HbA1c, but emphasizes the fact that HbA1c is
the only predictive factor for the development of microvascular
complications in T1DM. This is in accordance with the recent
guidelines of several international diabetes associations (ADA, IDF,
EASD, Italian Society of Diabetology, etc.) which point out that an
intensive therapeutic approach is mandatory right from the disease
onset, in order to reach optimum levels of HbA1c. In addition, our
study suggests that metabolic memory exerts a different influence on
diabetic retinopathy and microalbuminuria. By contrast, clinical,
immunological and other biochemical factors are only useful for
diagnosis and do not predict the onset of complications.
273C. Giordano et al. / European Journal of Internal Medicine 22 (2011) 266–2745. Learning points
• A close association between metabolic control and microvascular
complications in T1DM is well known.
• The DCCT experience widely demonstrated the clinical benefits of
preservation of β-cell function in preventing microvascular com-
plications, but only in intensively treated T1DM.
• Our study confirms the already known role of HbA1c, emphasizing
that in conventionally treated T1DM HbA1c is the only predictive
factor for the development of microvascular complications.
• In addition, our study suggests that the metabolic memory only
exerts a role in diabetic retinopathy development.
• Other clinical, immunological and biochemical factors are only
useful for diagnosis and do not predict the onset of complications.
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